FDA warned India-based website Cheap Medicine Shop for selling unapproved, misbranded injectable semaglutide to U.S. consumers.
What happened
FDA reviewed the website www.cheapmedicineshop.com on August 26, 2026 and September 2, 2026, and found it offering a semaglutide injection marketed as "Semanext Injection" for sale to U.S. consumers. The site claims the product is a weekly injectable used to control blood sugar in adults and to support weight loss and obesity management. FDA says there is no approved application for this product and its labeling lacks adequate directions for use.
What FDA found
The company sells a semaglutide injection that FDA has not approved.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 355(a))The product's labeling does not give adequate directions for use, which is required for a prescription drug.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The drug is a prescription product that is not safe for laypeople to use without a licensed practitioner's supervision.
FD&C Act section 503(b)(1) (21 U.S.C. 353(b)(1))Offering the misbranded drug for sale to U.S. consumers puts it into interstate commerce illegally.
FD&C Act section 301(a) (21 U.S.C. 331(a))The product is not exempt from the adequate-directions requirement because it is not approved in the United States.
21 CFR 201.115(a)
What FDA wants
FDA requests that the website stop offering unapproved and misbranded drugs for sale to U.S. consumers. The company must send a written response with corrective steps and supporting documents within 15 business days of receiving the letter, citing reference MARCS-CMS 737810.
Who should pay attention
- U.S. consumers who buy prescription drugs from overseas websites
- legitimate online pharmacies and telehealth prescribers of semaglutide
- quality and compliance teams at drug distributors and importers
This is a summary. Read the original letter on fda.gov.